Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease

Infliximab is commonly used in inflammatory bowel disease (IBD), however, differences in clinical response among patients are common. Several studies have considered the possibility that these differences are caused by genetic variability even if no unique marker has been yet identified in pediatric...

Descripción completa

Detalles Bibliográficos
Autores principales: Curci, Debora, Lucafò, Marianna, Cifù, Adriana, Fabris, Martina, Bramuzzo, Matteo, Martelossi, Stefano, Franca, Raffaella, Decorti, Giuliana, Stocco, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604212/
https://www.ncbi.nlm.nih.gov/pubmed/34145770
http://dx.doi.org/10.1111/cts.13075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604212/
https://www.ncbi.nlm.nih.gov/pubmed/34145770
http://dx.doi.org/10.1111/cts.13075

Ejemplares similares